| Identification | Back Directory | [Name]
2-[(1S)-1-[4-[6-[(4-Cyano-2-fluorophenyl)methoxy]-2-pyridinyl]-1-piperazinyl]ethyl]-1-[(2S)-2-oxetanylmethyl]-1H-benzimidazole-6-carboxylic acid | [CAS]
2775376-50-4 | [Synonyms]
2-[(1S)-1-[4-[6-[(4-Cyano-2-fluorophenyl)methoxy]-2-pyridinyl]-1-piperazinyl]ethyl]-1-[(2S)-2-oxetanylmethyl]-1H-benzimidazole-6-carboxylic acid | [Molecular Formula]
C31H31FN6O4 | [MOL File]
2775376-50-4.mol | [Molecular Weight]
570.62 |
| Chemical Properties | Back Directory | [Boiling point ]
805.3±65.0 °C(Predicted) | [density ]
1.39±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | [form ]
Solid | [pka]
3.96±0.30(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
GLP-1 receptor agonist 12 (compound 20A) is an agonist of GLP Receptor. GLP-1 receptor agonist 12 can be used in the study of diseases such as diabetes[1]. | [References]
[1] Wu JJ, et al. Benzimidazole derivatives as GLP-1R agonists and their preparation, pharmaceutical compositions and use in the treatment of diabetes. World Intellectual Property Organization, WO2022111624 A1. 2022-06-02. |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|